Daniele Andreis

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Journal: Cancer communications (London, England)
Published: April 28, 2024

A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial.

A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial.

Journal: Journal of medical Internet research
Published: January 22, 2021

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.

Journal: Therapeutic advances in medical oncology
Published: September 29, 2020

How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.

How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.

Journal: JCO oncology practice
Published: September 16, 2020

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.

Journal: The Journal of dermatological treatment
Published: September 03, 2020

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Journal: Journal of oncology
Published: January 21, 2019

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.

Journal: Cancer management and research
Published: September 15, 2018

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Journal: The oncologist
Published: August 27, 2018

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Journal: Translational oncology
Published: February 22, 2018

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Journal: BMC cancer
Published: November 29, 2017

Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study.

Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study.

Journal: BMJ open
Published: May 31, 2017

Sorafenib for the treatment of breast cancer.

Sorafenib for the treatment of breast cancer.

Journal: Expert opinion on pharmacotherapy
Published: March 25, 2017
Showing 1-12 of 29

Last Updated: 09/26/2026